Concert Pharmaceuticals Company Profile (NASDAQ:CNCE)

About Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CNCE
  • CUSIP: N/A
  • Web:
  • Market Cap: $297.37 million
  • Outstanding Shares: 22,562,000
Average Prices:
  • 50 Day Moving Avg: $15.42
  • 200 Day Moving Avg: $12.27
  • 52 Week Range: $7.11 - $19.11
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.77
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $137,999.00
  • Price / Sales: 2,154.85
  • Book Value: $3.33 per share
  • Price / Book: 3.96
  • EBIDTA: ($49,730,000.00)
  • Net Margins: -363.29%
  • Return on Equity: -33.68%
  • Return on Assets: -29.50%
  • Current Ratio: 15.93%
  • Quick Ratio: 15.93%
  • Average Volume: 477,343 shs.
  • Beta: 1.73
  • Short Ratio: 1.7

Frequently Asked Questions for Concert Pharmaceuticals (NASDAQ:CNCE)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) posted its quarterly earnings results on Tuesday, May, 2nd. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.06. The business earned $0.02 million during the quarter. Concert Pharmaceuticals had a negative return on equity of 33.68% and a negative net margin of 363.29%. View Concert Pharmaceuticals' Earnings History.

Where is Concert Pharmaceuticals' stock going? Where will Concert Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 12 month target prices for Concert Pharmaceuticals' stock. Their predictions range from $25.00 to $32.00. On average, they expect Concert Pharmaceuticals' stock price to reach $28.25 in the next year. View Analyst Ratings for Concert Pharmaceuticals.

What are analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (5/8/2017)
  • 2. Aegis analysts commented, "We do not anticipate the potential one quarter delay will have a material impact on our PT. CTP-543 is an oral JAK 1/2 inhibitor designed to treat alopecia areata. Within the US, approximately 650k patients are affected by alopecia areata. Oral CTP-543, a deuterated version of Jakafi, has received orphan designation from the FDA, and has progressed through multiple phase I trials for pharmacokinetics, crossover evaluation, and multiple ascending dose testing. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte ( INCY, Not Rated). (See Valuation Methodology and Risk Factors on Page 2)2 AEGIS CAPITAL CORP." (4/5/2017)

Are investors shorting Concert Pharmaceuticals?

Concert Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totalling 309,494 shares, a drop of 41.7% from the April 28th total of 530,478 shares. Based on an average trading volume of 207,679 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.7% of the company's stock are short sold.

Who are some of Concert Pharmaceuticals' key competitors?

Who owns Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.68%), Vanguard Group Inc. (3.02%), Driehaus Capital Management LLC (1.91%), Renaissance Technologies LLC (1.62%), Dimensional Fund Advisors LP (1.34%) and Prudential Financial Inc. (1.12%). Company insiders that own Concert Pharmaceuticals stock include Nancy Stuart, Pauline Mcgowan, Robert Silverman, Roger D Tung, Ronald W Barrett, Thomas G Auchincloss and Wilfred E Jaeger. View Institutional Ownership Trends for Concert Pharmaceuticals.

Who sold Concert Pharmaceuticals stock? Who is selling Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, UBS Group AG, AWM Investment Company Inc., Ingalls & Snyder LLC, Wells Fargo & Company MN, Nationwide Fund Advisors and Dimensional Fund Advisors LP. View Insider Buying and Selling for Concert Pharmaceuticals.

Who bought Concert Pharmaceuticals stock? Who is buying Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Lyon Street Capital LLC, Paulson & CO. Inc., KCG Holdings Inc., Prudential Financial Inc., Vanguard Group Inc., Virginia Retirement Systems ET AL and Dynamic Technology Lab Private Ltd. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Roger D Tung and Thomas G Auchincloss. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy Concert Pharmaceuticals stock?

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Concert Pharmaceuticals stock cost?

One share of Concert Pharmaceuticals stock can currently be purchased for approximately $13.18.

Analyst Ratings

Consensus Ratings for Concert Pharmaceuticals (NASDAQ:CNCE) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.25 (114.34% upside)

Analysts' Ratings History for Concert Pharmaceuticals (NASDAQ:CNCE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/5/2017Stifel NicolausReiterated RatingBuy$31.00LowView Rating Details
4/5/2017AegisReiterated RatingBuy$25.00LowView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$32.00N/AView Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
6/24/2015Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$24.00 -> $27.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Concert Pharmaceuticals (NASDAQ:CNCE)
Earnings by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Earnings History by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017($0.54)($0.60)$0.02 millionViewListenView Earnings Details
3/6/2017Q4 2016($0.66)($0.54)$0.02 millionViewListenView Earnings Details
11/8/2016Q316($0.63)($0.51)$0.06 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2($0.63)($0.60)$0.06 million$0.07 millionViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.66 million$0.06 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)($0.40)$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.77 million$1.31 millionViewN/AView Earnings Details
11/12/2014Q314($0.45)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.40)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Concert Pharmaceuticals (NASDAQ:CNCE)
Current Year EPS Consensus Estimate: $-2.65 EPS
Next Year EPS Consensus Estimate: $-1.12 EPS


Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Concert Pharmaceuticals (NASDAQ:CNCE)
Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 60.37%
Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.00View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.64View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.00View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Concert Pharmaceuticals (NASDAQ:CNCE)
Latest Headlines for Concert Pharmaceuticals (NASDAQ:CNCE)
DateHeadline logoConcert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals - May 24 at 12:42 PM logoConcert Pharma Gets Second FTC Request For Pending CTP-656 Deal - May 23 at 12:46 PM logoConcert Pharmaceuticals Receives Second Request from FTC Under HSR Act - May 22 at 12:33 PM logoConcert Pharma Falls After Clinical Hold on Hair Loss Drug - May 18 at 11:11 AM logoConcert Pharmaceuticals Announces Clinical Hold on CTP-543 Phase 2a Trial - May 17 at 4:25 PM logoConcert Pharma Announces Clinical Hold On CTP-543 Phase 2a Trial - May 17 at 11:32 AM logoConcert Pharma stock drops 10% after FDA puts hair loss drug on clinical hold - May 17 at 11:32 AM logoConcert Pharmaceuticals Inc (CNCE) Downgraded to Sell at Zacks Investment Research - May 8 at 6:38 PM logo-$0.62 EPS Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter - May 5 at 11:18 AM logoConcert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : May 4, 2017 - May 4 at 4:32 PM logoETFs with exposure to Concert Pharmaceuticals, Inc. : May 4, 2017 - May 4 at 4:32 PM logoConcert Pharmaceuticals Inc (CNCE) Sees Significant Increase in Short Interest - May 4 at 7:12 AM logoSomewhat Favorable Press Coverage Likely to Affect Concert Pharmaceuticals (CNCE) Share Price - May 3 at 11:46 PM logoConcert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 - May 3 at 4:22 PM logoConcert Pharmaceuticals Inc (CNCE) Posts Earnings Results, Misses Estimates By $0.06 EPS - May 3 at 2:48 PM logoEdited Transcript of CNCE earnings conference call or presentation 2-May-17 12:30pm GMT - May 3 at 9:36 AM logoConcert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata - May 2 at 1:49 PM logoConcert Pharmaceuticals Reports First Quarter 2017 Financial Results - May 2 at 1:49 PM logoInvestor Network: Concert Pharmaceuticals, Inc. to Host Earnings Call - May 2 at 1:49 PM logoConcert reports 1Q loss - May 2 at 1:49 PM logoSomewhat Favorable Press Coverage Extremely Likely to Impact Concert Pharmaceuticals (CNCE) Share Price - April 30 at 10:50 AM logoSomewhat Positive Press Coverage Very Unlikely to Affect Concert Pharmaceuticals (CNCE) Share Price - April 26 at 10:24 PM logoConcert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences - April 25 at 12:08 PM logoConcert Pharmaceuticals (CNCE) Receives Media Sentiment Score of 0.00 - April 22 at 11:59 AM logoConcert Pharmaceuticals (CNCE) Receiving Somewhat Favorable News Coverage, AlphaOne Reports - April 19 at 10:51 AM logoConcert Pharmaceuticals Inc (CNCE) Given Average Rating of "Buy" by Brokerages - April 18 at 5:00 PM logoSomewhat Critical News Coverage Extremely Likely to Effect Concert Pharmaceuticals (CNCE) Stock Price - April 16 at 10:17 AM logoConcert Pharmaceuticals Inc (CNCE) Sees Significant Decline in Short Interest - April 15 at 11:56 AM logoZacks: Brokerages Anticipate Concert Pharmaceuticals Inc (CNCE) to Announce -$0.54 Earnings Per Share - April 14 at 11:28 AM logoETFs with exposure to Concert Pharmaceuticals, Inc. : April 7, 2017 - April 7 at 4:23 PM logoConcert Pharmaceuticals Inc (CNCE) PT Set at $31.00 by Stifel Nicolaus - April 5 at 7:21 PM logoConcert Pharmaceuticals Inc (CNCE) Earns Buy Rating from Aegis - April 5 at 2:13 PM logoWhy Concert Pharmaceuticals Is Music to Investors' Ears - March 26 at 4:14 PM logoWill Concert Pharmaceuticals (CNCE) Continue to Surge Higher? - March 24 at 9:43 PM logoWill Concert Pharmaceuticals (CNCE) Continue to Surge Higher? - Nasdaq - March 24 at 4:41 PM logoConcert Pharmaceuticals Inc (CNCE) Receives Average Rating of "Buy" from Analysts - March 24 at 1:01 PM logoMoving Average Crossover Alert: Concert Pharmaceuticals (CNCE) - March 17 at 3:51 PM logoConcert Pharmaceuticals Inc (CNCE) Upgraded at Zacks Investment Research - March 9 at 6:30 PM logoCONCERT PHARMACEUTICALS, INC. Financials - March 9 at 4:56 PM logoConcert Pharmaceuticals Inc (CNCE) Stock Rating Reaffirmed by Aegis - March 8 at 7:01 PM Coverage Initiated on Concert Pharmaceuticals, Price Surges - March 8 at 5:06 PM logoConcert Pharmaceuticals Inc (CNCE) Price Target Raised to $31.00 at Stifel Nicolaus - March 7 at 11:57 PM logoConcert Pharmaceuticals (CNCE) Presents At Cowen and Company 37th Annual Health Care Conference - March 7 at 4:24 PM logoEdited Transcript of CNCE earnings conference call or presentation 6-Mar-17 1:30pm GMT - March 7 at 4:24 PM logoHarry Boxer’s six biotechnology stocks to watch - March 7 at 4:24 PM logoBUZZ-US STOCKS ON THE MOVE-TG Therapeutics, Advaxis, Concert Pharma, GoPro - Nasdaq - March 7 at 12:18 PM logoVertex to Buy Concert's Cystic Fibrosis Candidate for $160M - March 7 at 12:18 PM logoWhy Concert Pharmaceuticals Stock Is Soaring Today - March 6 at 4:18 PM logoMonday’s Top Health Care Stocks Screaming Higher - March 6 at 4:18 PM logo3:09 am Concert Pharmaceuticals presents Phase 1 results CTP-543; on Track to begin Phase 2a Trial in Q1 - March 6 at 10:31 AM



Concert Pharmaceuticals (CNCE) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff